HyphAeon: Attention on Evolution Across Deep Time Transforms Comparative Genomics

Kosakovsky Pond, S. L.; Weaver, S.; Callan, D.; Zehr, J. D.; Lucaci, A. G.; Verdonk, H.; Selberg, A.; Brown, G.; Chikina, M.; Clark, N. L.; Makova, K. D.; Martin, D. P.; Nekrutenko, A.

doi:10.64898/2026.09.06.749597

bioRxiv · 10.64898/2026.09.06.749597

HyphAeon: Attention on Evolution Across Deep Time Transforms Comparative Genomics

Kosakovsky Pond, S. L.·Weaver, S.·Callan, D.·Zehr, J. D.·Lucaci, A. G.·Verdonk, H.·Selberg, A.·Brown, G.·Chikina, M.·Clark, N. L.·Makova, K. D.·Martin, D. P.·Nekrutenko, A.

View original source ↗Export metadata ↓

Abstract

Detecting Darwinian natural selection is fundamental to evolutionary biology and functional genomics, yet standard methods based on phylogenetic models that estimate the ratio of non-synonymous to synonymous substitution rates (dN/dS) fail to scale with modern genomic volumes. Fitting continuous-time Markov substitution matrices across dense trees with hundreds of species requires extensive compute, forcing comparative genomics to rely on aggressive taxon subsampling or static whole-tree summaries that dilute transient adaptive bursts. Here we present HyphAeon, a lightweight (~1.91M parameter backbone, 2.46M across the full multi-task suite) phylogeny-informed foundation transformer trained to amortize the detection of episodic diversifying selection across 742-species mammalian coding alignments (17,186 genes, 9.77 x 10^6 codons). HyphAeon approaches the discriminative accuracy of numerical maximum-likelihood selection tests (MEME) across episodic burst regimes (ROC-AUC up to 0.942, mean 0.659; empirical Precision-Recall lift up to 25.8x, mean 7.7x; rank concordance up to rho = 0.983) while executing >1,000x faster per locus (averaging <1 ms per site across genome-wide scans) and >10,000x faster at proteome scale, generalizing outside its mammalian training distribution without retraining. Beyond accelerating classical tests, embedding molecular evolution into a differentiable geometric latent space enables analytical capabilities inaccessible to static dN/dS models: (1) targeted alignment artifact correction via counterfactual attribution; (2) macromolecular contact recovery and multi-site epistatic sectors (CESI); (3) directional phenotype-to-genotype attribution in lineage space (PARS); and (4) continuous temporal surveillance regression that tracks positive sweep velocities across longitudinal cohorts (evaluated across 12,167 timestamped genomes and benchmarked against external frequencies from >9.34 million genomes), rescuing adaptive substitutions obscured by post-fixation dilution. By bridging statistical phylogenetics with geometric representation learning, HyphAeon establishes comparative genomics as an interactive, high-throughput computational framework for evolutionary discovery.

Explore related subjects

bioinformatics Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Kosakovsky Pond, S. L., Weaver, S., Callan, D., Zehr, J. D., Lucaci, A. G., Verdonk, H., Selberg, A., Brown, G., Chikina, M., Clark, N. L., Makova, K. D., Martin, D. P., Nekrutenko, A.. 2026-09-10. HyphAeon: Attention on Evolution Across Deep Time Transforms Comparative Genomics. https://doi.org/10.64898/2026.09.06.749597

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Heterogeneous Graph Contrastive Learning for Drug-Gene-Disease Motif Prediction

Drug repurposing and target discovery offer critical strategies for advancing therapeutic development by uncovering the potential biological pathways and novel associations among drugs, genes, and diseases. However, experimental discovery remains expensive and time-consuming, which limits the scalability of large-scale studies. In addition, existing computational approaches often struggle to effectively integrate heterogeneous biomedical data, capture the complex higher-order topological signatures of biological interactomes, and generalize to unseen entities. Here, we present HANAMI (Heterogeneous grAph coNtrastive leArning for drug-gene-disease Motif predIction), a multi-view deep graph learning framework designed to model complex interactions among drugs, genes, and diseases. HANAMI integrates diverse heterogeneous biomedical knowledge, including chemical structures, genomic sequences, and clinical phenotypes, and leverages relation-aware topology encoding, structure-aware aggregation, and contrastive learning to enable accurate motif prediction with biological context from the network. Systematic evaluation on benchmark datasets shows that HANAMI achieves up to 6% improvements over existing state-of-the-art methods in predicting drug-gene-disease motifs. The framework further demonstrates strong inductive generalization, maintaining an [~]18% performance advantage in zero-shot settings involving previously unseen entities. Beyond predictive performance, HANAMI effectively prioritizes drug-disease relationships investigated in Phase II or III trials while identifying candidate genes that suggest plausible mechanistic links. Together, HANAMI provides a computational framework for interpreting complex biomedical interactions, offering a scalable foundation to accelerate drug repurposing and therapeutic innovation.

bioinformatics↗

bioRxiv2026

PTMExplorer: A Multi-Dimensional Integrative Visualization Platform for Protein Post-Translational Modification Function and Structure

Deciphering the functions of post-translational modifications (PTMs) is a critical bridge connecting large-scale modification proteomics data to mechanistic studies. However, most existing tools for visualizing PTM omics data are limited to site catalogs or single-dimensional feature displays. They lack the capability to simultaneously map user-derived differential modification sites onto multi-dimensional contexts, including protein three-dimensional (3D) structure, evolutionary conservation, functional sites, and disease associations. This limitation makes it difficult for researchers to rapidly assess the biological importance of candidate sites from among a vast number of differentially modified sites. Here, we present PTMExplorer, an interactive platform for the multi-dimensional visualization of protein PTMs. PTMExplorer comprises three core modules: PTM Inspector, built upon ProtVista, provides a multi-track, sequence-feature integrated view incorporating intrinsically disordered region (IDR) prediction (via flDPnn), surface accessibility calculation (via FreeSASA), and UniProt functional annotations; PTM 3D Locator, leveraging the Nightingale/Mol* engine, anchors modification sites onto AlphaFold/Protein Data Bank (PDB) 3D structures through residue mapping via PDBe-SIFTS; and PTM Overview, utilizing the R circlize package, presents a panoramic polar circos plot illustrating modification distribution and inter-group differential regulation. Additionally, three major disease-associated modification databases (PTMD, qPTM, and PhosCancer) are integrated as PTM-Disease Nexus, enabling co-localization comparison between user-defined differential sites and reported disease-related sites. PTMExplorer currently supports eight model organisms, accepts user-uploaded differential analysis results, and provides multi-dimensional annotations and various visualization options (https://www.bioladder.cn/PTMExplorer/). Using a multi-omics dataset from hepatocellular carcinoma (18 patients, 9 modification types) as a case study, we demonstrate the practical utility of PTMExplorer in screening potential biomarkers, revealing multi-modification coordination mechanisms, and distinguishing between absolute and relative quantification patterns.

bioinformatics↗

bioRxiv2026

Integrative analysis of the MDM2 promoter switch and cellular lineage plasticity in colorectal cancer: a contrast between the autonomous-proliferation type (CIN/CMS2) and the environment-adaptive type (MSI/gastric metaplasia)

Background: Biomarkers that stratify colorectal cancer (CRC) by therapeutic responsiveness and are measurable directly in biopsy specimens remain insufficiently established. We investigated whether usage of the dual MDM2 promoters (P1/P2) acts as a molecular switch separating two diametrically opposed CRC phenotypes: a chromosomal instability type and an environment adaptive type (microsatellite instability/serrated pathway with gastric metaplasia). Methods: Sixty three organoid samples from 22 patients with CRC were classified morphologically by deep learning (VGG16) and molecularly by an MDM2 Splicing Index derived from expression arrays. The P1 and P2 signatures (gene sets characterizing P1 and P2dominant samples) were externally validated in TCGA-COAD/READ (n = 624) and GSE39582 (n = 536), 1,160 cases in total, and therapeutic implications were tested in public cell line panels (GDSC2, DepMap) and in 65 lines of an independent patient derived CRC organoid biobank. Results: Deep learning morphological classification reached 98.5% test accuracy (64/65), and morphology corresponded to P1/P2 isoform usage: Type1 (compact glandular) morphology predominated in P1 dominant samples (median Type1 fraction 0.826 versus 0.444) and non Type1 (cystic mucinous) morphology in P2 dominant samples (AUC 0.79). Both signatures differed across the four consensus molecular subtypes , and the P2 signature was higher in mismatch repair deficient (microsatellite-unstable) tumors. Promoter usage quantified directly (P2_index) was higher in TP53 wild type tumors , consistent with P2 being p53-inducible. TP53 wild type cell lines were more sensitive to the MDM2 inhibitor Nutlin 3a and were more dependent on MDM2 in the DepMap CRISPR screen ; among 198 GDSC2 drugs, Nutlin 3a correlated most strongly with the P2 score. In the independent biobank, TP53 wild type lines (17) were more sensitive to nutlin-3 than mutant lines (48) (median log(IC50) 1.386 versus 4.283). Conclusions: MDM2 promoter choice (P1/P2) co-varies with the lineage identity of cancer cells and with the secretory, mucin rich character of the tumor tissue, consistent with a molecular-switch role alongside p53 suppression. The MDM2 P1/P2 ratio, measurable by RT qPCR or targeted NGS, is a candidate molecular-classification and therapeutic-stratification biomarker corresponding robustly to CMS, MSI, and TP53 mutation status.

bioinformatics↗